Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 5/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3094410 | 1.00 | GAA (0.45) | GAAL3MBTL1KMT2AMEN1POLB | |
| SCHEMBL3190543 | 1.00 | GAA (0.45) | GAAL3MBTL1KMT2AMEN1POLB | |
| SCHEMBL82476 | 0.87 | KMT2A (0.51) | GAAL3MBTL1KMT2AMEN1POLB | |
| SCHEMBL16373718 | 0.85 | GAA (0.59) | GAAL3MBTL1KMT2AMEN1MAPT | |
| SCHEMBL1190859 | 0.85 | OXTR (0.51) | GAAL3MBTL1KMT2AMEN1MAPT | |
| SCHEMBL1190645 | 0.85 | OXTR (0.51) | GAAL3MBTL1KMT2AMEN1MAPT | |
| SCHEMBL1190642 | 0.85 | OXTR (0.51) | GAAL3MBTL1KMT2AMEN1MAPT | |
| SCHEMBL4907547 | 0.82 | GAA (0.54) | GAAL3MBTL1KMT2AMEN1MAPT | |
| SCHEMBL4905603 | 0.82 | GAA (0.54) | GAAL3MBTL1KMT2AMEN1MAPT | |
| SCHEMBL5316912 | 0.82 | GAA (0.54) | GAAL3MBTL1KMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1765803-B1 | QUATERNARY SALT CCR2 ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2016-03-09 | — | — | EP | disclosed |
| US-7799824-B2 | Quaternary salt CCR2 antagonists | ORAPHARMA, INC. (US) | 2010-09-21 | — | — | US | disclosed |
| US-20060293379-A1 | Quaternary salt CCR2 antagonists | KENVUE BRANDS LLC | 2006-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293379-A1 | Quaternary salt CCR2 antagonists | CCR2, CCR1, CXCR2 | GAA 4725/4885L3MBTL1 3739/4885KMT2A 1470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.